National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 15712 [2010-7089]
Download as PDF
<![CDATA[
15712
Federal Register / Vol. 75, No. 60 / Tuesday, March 30, 2010 / Notices
3101 or darakn@mail.nih.gov for more
information.
mFPR2 Transgenic and Knockout
Mouse Models for Alzheimer’s and
Other Inflammatory Diseases
Description of Invention: Human
Formyl Peptide-Like Receptor 1
(hFPLR1) has been implicated in host
defense for disease processes including
Alzheimer’s disease, infection, and
other inflammatory diseases. hFPLR1
and its mouse homologue Formyl
Peptide Receptor 2 (mFPR2) are
G-protein coupled receptors that are
expressed at high levels on phagocytic
leukocytes, mediating leukocyte
chemotaxis and activation in response
to a number of pathogen- and hostderived peptides. Activation of hFPRL1/
mFPR2 by lipoxin A4 may play a role
in preventing and resolving
inflammation. Also, hFPRL1/mFPR2 has
been shown to mediate the chemotactic
activity of amyloid beta 1-42, a key
pathogenic peptide in Alzheimer’s
disease.
Available for licensing are mice
expressing the mFPR2 transgene on
either the FVB or C58BL background, as
well as mFPR2 knockout mice on the
C57BL background. These mice are
anticipated to be highly useful in the
study of a wide variety of inflammatory,
infectious, immunologic and
neurodegenerative diseases.
jlentini on DSKJ8SOYB1PROD with NOTICES
Applications
• Drug development model for
Alzheimer’s disease and other
inflammatory diseases.
• Tool to probe the role of hFPRL1/
mFPR2 in host responses in a variety of
disease processes, including
inflammatory, infectious, immunologic,
and neurodegenerative disease.
Inventors: Ji Ming Wang et al. (NCI)
Publications
1. K Chen, Y Le, Y Liu, W Gong, G
Ying, J Huang, T Yoshimura, L
Tessarollo, JM Wang. Cutting Edge: A
Critical Role for the G Protein-Coupled
Receptor mFPR2 in Airway
Inflammation and Immune Responses. J
Immunol. 2010 Mar 3. Epub ahead of
print. [PubMed: 20200280.]
2. K Chen, P Iribarren, J Hu, J Chen,
W Gong, EH Cho, S Lockett, NM
Dunlop, and JM Wang. Activation of
Toll-like receptor 2 on microglia
promotes cell uptake of Alzheimer
disease-associated amyloid beta peptide.
J Biol Chem. 2006 Feb 10;281(6):3651–
3659. [PubMed: 16339765.]
3. H Yazawa, ZX Yu, Takeda, Y Le, W
Gong, VJ Ferrans, JJ Oppenheim, CC Li,
and JM Wang. Beta amyloid peptide
(Abeta42) is internalized via the G-
VerDate Nov<24>2008
16:22 Mar 29, 2010
Jkt 220001
protein-coupled receptor FPRL1 and
forms fibrillar aggregates in
macrophages. FASEB J. 2001
Nov;15(13):2454–2462. [PubMed:
11689470.]
4. YH Cui, Y Le, W Gong, P Proost,
J Van Damme, WJ Murphy, and JM
Wang. Bacterial lipopolysaccharide
selectively up-regulates the function of
the chemotactic peptide receptor formyl
peptide receptor 2 in murine microglial
cells. J Immunol. 2002 Jan 1;168(1):434–
442. [PubMed: 11751990.]
Patent Status: HHS Reference No.
E–303–2006/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: This technology is
available as a research tool under a
Biological Materials License.
Licensing Contact: Tara Kirby, PhD;
301–435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute—
Frederick, Laboratory of Molecular
Immunoregulation, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize mFPR2 Transgenic and
Knockout Mouse Models for
Alzheimer’s and Other Inflammatory
Diseases. Please contact John D. Hewes,
PhD at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Dated: March 23, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–6966 Filed 3–29–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Ancillary Studies in
Immunomodulation Clinical Trials.
Date: April 22, 2010.
Time: 11:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817.
(Telephone Conference Call)
Contact Person: Paul A. Amstad, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
402–7098, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: March 24, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–7089 Filed 3–29–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the AIDS
Research Advisory Committee, NIAID.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: AIDS Research
Advisory Committee, NIAID, AIDS Vaccine
Research Subcommittee.
Date: May 25–26, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To discuss follow-up studies to
the recent RV144 vaccine efficacy trial, and
to discuss the use of the nonhuman primate
model in AIDS vaccine research.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: James A. Bradac, PhD,
Program Official, Preclinical Research and
Development Branch, Division of AIDS,
Room 5116, National Institutes of Health/
NIAID, 6700B Rockledge Drive, Bethesda,
MD 20892–7628. 301–435–3754.
jbradac@mail.nih.gov.
E:\FR\FM\30MRN1.SGM
30MRN1
]]>Agencies
[Federal Register Volume 75, Number 60 (Tuesday, March 30, 2010)]
[Notices]
[Page 15712]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-7089]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Ancillary Studies in
Immunomodulation Clinical Trials.
Date: April 22, 2010.
Time: 11:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive,
Bethesda, MD 20817. (Telephone Conference Call)
Contact Person: Paul A. Amstad, PhD, Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities, NIAID/
NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616,
301-402-7098, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: March 24, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-7089 Filed 3-29-10; 8:45 am]
BILLING CODE 4140-01-P
